Nuvectis Pharma Inc (NVCT)

Currency in USD
8.63
-0.29(-3.25%)
Closed·
8.630.00(0.00%)
·
NVCT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.558.95
52 wk Range
5.5511.52
Key Statistics
Prev. Close
8.63
Open
8.89
Day's Range
8.55-8.95
52 wk Range
5.55-11.52
Volume
35.69K
Average Volume (3m)
80.82K
1-Year Change
9.9363%
Book Value / Share
0.72
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NVCT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
16.80
Upside
+94.67%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Nuvectis Pharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Compare NVCT to Peers and Sector

Metrics to compare
NVCT
Peers
Sector
Relationship
P/E Ratio
−7.9x−2.6x−0.5x
PEG Ratio
0.41−0.030.00
Price/Book
12.4x2.7x2.6x
Price / LTM Sales
-4.3x3.3x
Upside (Analyst Target)
107.6%148.5%45.6%
Fair Value Upside
Unlock16.5%4.9%Unlock

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 16.80
(+94.67% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy10.00+15.87%-Maintain03/12/2025
H.C. Wainwright
Buy10.00+15.87%-Maintain28/10/2025
H.C. Wainwright
Buy10.00+15.87%15.00Maintain04/08/2025
H.C. Wainwright
Buy15.00+73.81%11.00Maintain30/04/2025
Maxim Group
Buy17.00+96.99%-New Coverage02/04/2025

Earnings

Latest Release
Feb 12, 2026
EPS / Forecast
-0.31 / -0.254
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

15.02
KELYB
-0.07%
5.77
FORR
+2.85%
1.78
FATN
-0.56%
19.22
CMCO
-3.22%
4.85
CVRX
+2.32%

FAQ

What Is the Nuvectis Pharma (NVCT) Share Price Today?

The live Nuvectis Pharma share price today is 8.63

What Stock Exchange Does Nuvectis Pharma (NVCT) Trade On?

Nuvectis Pharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Nuvectis Pharma?

The stock symbol (also called a 'ticker') for Nuvectis Pharma is "NVCT."

What Is the Current Nuvectis Pharma Market Cap?

As of today, Nuvectis Pharma market capitalisation is 228.62M.

What Is Nuvectis Pharma's (NVCT) Earnings Per Share (TTM)?

The Nuvectis Pharma EPS is currently -1.32 (Trailing Twelve Months).

When Is the Next Nuvectis Pharma Earnings Date?

Nuvectis Pharma's next earnings report will be released on 12/05/2026.

Is NVCT a Buy or Sell From a Technical Analyst Perspective?

Based on today's Nuvectis Pharma moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Nuvectis Pharma Stock Split?

Nuvectis Pharma has split 0 times. (See the NVCT stock split history page for full effective split date and price information.)

How Many Employees Does Nuvectis Pharma Have?

Nuvectis Pharma has 13 employees.

What is the current trading status of Nuvectis Pharma (NVCT)?

As of 19/02/2026, Nuvectis Pharma (NVCT) is trading at a price of 8.63, with a previous close of 8.63. The stock has fluctuated within a day range of 8.55 to 8.95, while its 52-week range spans from 5.55 to 11.52.

What Is Nuvectis Pharma (NVCT) Price Target According to Analysts?

The average 12-month price target for Nuvectis Pharma is USD16.80, with a high estimate of USD20 and a low estimate of USD10. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +94.67% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.